The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Interstitial Lung Disease in Japanese Patients with Lung Cancer: A Cohort and Nested Case-Control Study
Abstract
RATIONALE: Interstitial lung disease (ILD) occurs in Japanese patients with non-small cell lung cancer (NSCLC) receiving gefitinib. OBJECTIVES: To elucidate risk factors for ILD in Japanese patients with NSCLC during treatment with gefitinib or chemotherapy. METHODS: In a prospective epidemiologic cohort, 3,166 Japanese patients with advanced/recurrent NSCLC were followed for 12 weeks on 250 mg gefitinib (n = 1,872 treatment periods) or chemotherapy (n = 2,551). Patients who developed acute ILD (n = 122) and randomly selected control subjects (n = 574) entered a case-control study. Adjusted incidence rate ratios were estimated from case-control data by odds ratios (ORs) with 95% confidence intervals (CIs) using logistic regression. Crude (observed) incidence rates and risks were calculated from cohort data. MEASUREMENTS AND MAIN RESULTS: The observed (unadjusted) incidence rate over 12 weeks was 2.8 (95% CI, 2.3-3.3) per 1,000 person-weeks, 4.5 (3.5-5.4) for gefitinib versus 1.7 (1.2-2.2) for chemotherapy; the corresponding observed naive cumulative incidence rates at the end of 12-week follow-up were 4.0% (3.0-5.1%) and 2.1% (1.5-2.9%), respectively. Adjusted for imbalances in risk factors between treatments, the overall OR for gefitinib versus chemotherapy was 3.2 (1.9-5.4), elevated chiefly during the first 4 weeks (3.8 [1.9-7.7]). Other ILD risk factors in both groups included the following: older age, poor World Health Organization performance status, smoking, recent NSCLC diagnosis, reduced normal lung on computed tomography scan, preexisting chronic ILD, concurrent cardiac disease. ILD-related deaths in patients with ILD were 31.6% (gefitinib) versus 27.9% (chemotherapy); adjusted OR, 1.05 (95% CI, 0.3-3.2). CONCLUSIONS: ILD was relatively common in these Japanese patients with NSCLC during therapy with gefitinib or chemotherapy, being higher in the older, smoking patient with preexisting ILD or poor performance status. The risk of developing ILD was higher with gefitinib than chemotherapy, mainly in the first 4 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Variable Selection for Propensity Score Models
Brookhart, M. A., Schneeweiss, S., Rothman, K. J., Glynn, R. J., Avorn, J., & Stürmer, T. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj149 · Cited by 2,336
Sandler, A. B., Nemunaitis, J., Denham, C., von Pawel, J., Cormier, Y., Gatzemeier, U., Mattson, K., Manegold, C., Palmer, M. C., Gregor, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.122 · Cited by 712
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Franklin, W. A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J. R., Ciuleanu, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3958 · Cited by 703
Self-citationPao, W., & Miller, V. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.799 · Cited by 631
Acute Exacerbation in Idiopathic Pulmonary Fibrosis
Kondoh, Y., Taniguchi, H., Kawabata, Y., Yokoi, T., Suzuki, K., & Takagi, K. (1993) · Chest · doi:10.1378/chest.103.6.1808 · Cited by 457
Severe acute interstitial pneumonia and gefitinib
Inoue, A., Saijo, Y., Maemondo, M., Gomi, K., Tokue, Y., Kimura, Y., Ebina, M., Kikuchi, T., Moriya, T., & Nukiwa, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12190-3 · Cited by 450
Pulmonary Drug Toxicity: Radiologic and Pathologic Manifestations
Rossi, S. E., Erasmus, J. J., McAdams, H. P., Sporn, T. A., & Goodman, P. C. (2000) · RadioGraphics · doi:10.1148/radiographics.20.5.g00se081245 · Cited by 449
Ando, M., Okamoto, I., Yamamoto, N., Takeda, K., Tamura, K., Seto, T., Ariyoshi, Y., & Fukuoka, M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9866 · Cited by 362
Self-citationKudoh, S., Takeda, K., Nakagawa, K., Takada, M., Katakami, N., Matsui, K., Shinkai, T., Sawa, T., Goto, I., Semba, H., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1044 · Cited by 360 · cited 1×
“It is recognized that ILD is more common in Japan than elsewhere (5, 6 , 12, 13).”
BackgroundRadiation-induced and chemotherapy-induced pulmonary injury
Abid, S. H., Malhotra, V., & Perry, M. C. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200107000-00006 · Cited by 274
What Does the Odds Ratio Estimate in a Case-Control Study?
PEARCE, N. (1993) · International Journal of Epidemiology · doi:10.1093/ije/22.6.1189 · Cited by 266 · cited 1×
“Control subjects for the nested case-control study were sampled using incidence density sampling, and consequently the odds ratio (OR) obtained from the case-control analysis estimates the study incidence rate ratio (and approximately estimates the risk ratio) ( 16 ).”
MethodThe epidemiology of interstitial lung disease and its association with lung cancer
Raghu, G., Nyberg, F., & Morgan, G. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602061 · Cited by 213
Self-citationChang, A., Parikh, P., Thongprasert, S., Tan, E. H., Perng, R.-P., Ganzon, D., Yang, C.-H., Tsao, C.-J., Watkins, C., Botwood, N., et al. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30415-9 · Cited by 181
Self-citationTakano, T., Ohe, Y., Kusumoto, M., Tateishi, U., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., Tamura, T., et al. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.01.010 · Cited by 176
Rice, A. B., Moomaw, C. R., Morgan, D. L., & Bonner, J. C. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65115-2 · Cited by 158
Suzuki, H., Aoshiba, K., Yokohori, N., & Nagai, A. (2003) · PubMed · Cited by 129
Gefitinib Prevents Bleomycin-induced Lung Fibrosis in Mice
Ishii, Y., Fujimoto, S., & Fukuda, T. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200509-1534oc · Cited by 111
Hotta, K., Kiura, K., Tabata, M., Harita, S., Gemba, K., Yonei, T., Bessho, A., Maeda, T., Moritaka, T., Shibayama, T., et al. (2005) · The Cancer Journal · doi:10.1097/00130404-200509000-00010 · Cited by 75
Interstitial Lung Disease in Lung Cancer: Separating Disease Progression from Treatment Effects
Danson, S. J., Blackhall, F. H., Hulse, P. A., & Ranson, M. (2005) · Drug Safety · doi:10.2165/00002018-200528020-00002 · Cited by 62
High prevalence of drug-induced pneumonia in Japan
Azuma, A. (2007) · Medical Entomology and Zoology · Cited by 57
Update in Diffuse Parenchymal Lung Disease 2007
Wells, A. U., & Hogaboam, C. M. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-056up · Cited by 43
An update on epidermal growth factor receptor inhibitors
Modi, S., & Seidman, A. D. (2002) · Current Oncology Reports · doi:10.1007/s11912-002-0047-6 · Cited by 31
Update in Diffuse Parenchymal Lung Disease 2006
Wells, A. U., & Hogaboam, C. M. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-052up · Cited by 25
Cited by
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Self-citationModi, S., Park, H., Murthy, R. K., Iwata, H., Tamura, K., Tsurutani, J., Moreno-Aspitia, A., Doi, T., Sagara, Y., Redfern, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02318 · Cited by 787
Drug-Induced Interstitial Lung Disease: A Systematic Review
Skeoch, S., Weatherley, N., Swift, A. J., Oldroyd, A., Johns, C., Hayton, C., Giollo, A., Wild, J. M., Waterton, J. C., Buch, M., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7100356 · Cited by 422
Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases
Ishikawa, N., Hattori, N., Yokoyama, A., & Kohno, N. (2012) · Respiratory Investigation · doi:10.1016/j.resinv.2012.02.001 · Cited by 402
Metadata
- Authors
- Kudoh, S., Kato, H., Nishiwaki, Y., Fukuoka, M., Nakata, K., Ichinose, Y., Tsuboi, M., Yokota, S., Nakagawa, K., Suga, M., Japan Thoracic Radiology Group, Jiang, H., Itoh, Y., Armour, A., Watkins, C., Higenbottam, T., & Nyberg, F.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06-15
- Volume
- 177
- Issue
- 12
- Pages
- 1348-1357
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W1913616561
- Cited by
- 477
- References
- 24
- FWCI
- 20.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.